Metadata record for the manuscript: Analytical validation of a targeted liquid biopsy assay with comprehensive molecular and clinical profiling of circulating tumor DNA from 1,000 patients
Lists
Only you see this
Abstract
<b>Summary</b><br> This metadata record provides details of the data supporting the claims of the related manuscript: “Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA”. The related study presents extensive validation studies of the Tempus xF liquid biopsy assay (a 105-gene, hybrid-capture, next-generation sequencing (NGS) assay that detects single-nucleotide variants, insertions/deletions, copy number variants, and chromosomal rearrangements) using reference standards, cell lines, and patient samples that establish high sensitivity, specificity, and accuracy in variant detection. Type of data: liquid biopsy Subject of data: <i>Homo sapiens</i> Sample size: 1000 Recruitment: randomly selected cancer patients who had clinical plasma specimens sequenced with the xF panel at CAP/CLIA-certified Tempus Labs, Inc. <b>Data access</b> The de-identified clinical data that support findings from the retrospective profiling study have been deposited in the Vivli repository (https://vivli.org/) in the file ‘xf_1000_De-identified_Phenotypic_Data_and_ctFE.tsv’ under the following accession: T20.01 (https://search.vivli.org/?search=T20.01). Access is restricted, and interested parties must make an authorised request to the Vivli repository. The following supplementary tables are openly available in accessible format as part of this <i>figshare </i>data record: - Supplementary Table 4.xlsx. This table underlies Figure 1 of the related article: Inter-assay comparison between Tempus xF, ddPCR, and Tempus xT results. - Supplementary Table 1. Analysis Variants detected by the Tempus xF assay - Supplementary Table 2. Overview of samples and experiments - Supplementary Table 3. Probabilistic noise filtering methodology improves variant Raw data from the validation experiments were generated and analysed as part of a CAP/CLIA validation. As such, they are not publicly available but have been thoroughly reviewed by those governing authorities. <b>Corresponding author(s) for this study</b> Nike Beaubier, Tempus Labs, Chicago, IL, USA. [email protected].<br> <br> <b></b> <b>Study approval </b> The study protocol was submitted to the Advarra Institutional Review Board (IRB), which determined the research was exempt from IRB oversight and approved a waiver of HIPAA authorization for this study.
BibTeX
@inproceedings{finkle2021metadata,
author = {Justin D. Finkle and Hala Boulos and Terri M. Driessen and Christine Lo and Richard Blidner and Ashraf Hafez and Aly A Khan and Ariane Lozac’hmeur and Kelly E. McKinnon and Jason Perera and Wei Zhu and Afshin Dowlati and Kevin P. White and Robert Tell and Nike Beaubier},
title = {{Metadata record for the manuscript: Analytical validation of a targeted liquid biopsy assay with comprehensive molecular and clinical profiling of circulating tumor DNA from 1,000 patients}},
booktitle = {Figshare},
year = {2021},
doi = {10.6084/m9.figshare.14672673},
}Loading related content...